| Literature DB >> 18982120 |
Henry Markram1, Tania Rinaldi, Kamila Markram.
Abstract
Autism is a devastating neurodevelopmental disorder with a polygenetic predisposition that seems to be triggered by multiple environmental factors during embryonic and/or early postnatal life. While significant advances have been made in identifying the neuronal structures and cells affected, a unifying theory that could explain the manifold autistic symptoms has still not emerged. Based on recent synaptic, cellular, molecular, microcircuit, and behavioral results obtained with the valproic acid (VPA) rat model of autism, we propose here a unifying hypothesis where the core pathology of the autistic brain is hyper-reactivity and hyper-plasticity of local neuronal circuits. Such excessive neuronal processing in circumscribed circuits is suggested to lead to hyper-perception, hyper-attention, and hyper-memory, which may lie at the heart of most autistic symptoms. In this view, the autistic spectrum are disorders of hyper-functionality, which turns debilitating, as opposed to disorders of hypo-functionality, as is often assumed. We discuss how excessive neuronal processing may render the world painfully intense when the neocortex is affected and even aversive when the amygdala is affected, leading to social and environmental withdrawal. Excessive neuronal learning is also hypothesized to rapidly lock down the individual into a small repertoire of secure behavioral routines that are obsessively repeated. We further discuss the key autistic neuropathologies and several of the main theories of autism and re-interpret them in the light of the hypothesized Intense World Syndrome.Entities:
Keywords: amygdala; autism; connectivity; microcircuit; neocortex; plasticity; valproic acid
Year: 2007 PMID: 18982120 PMCID: PMC2518049 DOI: 10.3389/neuro.01.1.1.006.2007
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Potential environmental triggers for autism.
| Teratogenic insult | Background | Time of insult to cause ASD | Disorder | Number of people studied (% ASD) | Study | Reference |
|---|---|---|---|---|---|---|
| Maternal rubella infection | Infectious disease caused by the rubella virus | First 8 weeks of gestation | ASD, CRS | 243 (7%) | PS | Chess, |
| PS | Chess, | |||||
| PS | Chess and Fernandez, | |||||
| Ethanol | Prenatal alcohol exposure may cause FAS, which shares behavioural anomalies with autism | Unclear, animal studies suggest 3–5 week of gestation | ASD, FAS | 6 | CR | Nanson, |
| 3 | CR | Harris et al., | ||||
| 24 (12.5%) | PS | Aronson et al., | ||||
| Misoprostol | Produces a dose-related inhibition of gastric acid and pepsin secretion. Enhances mucosal resistance to injury. Effective anti-ulcer agent. Oxytocic properties. Used to induce abortion. | ASD, MS | 23 (26.1%) | PS | Bandim et al., | |
| Thalidomide | Originally introduced as a non-barbiturate hypnotic, but was withdrawn from the market due to its' teratogenic effects. | Days 20-24 of gestation | ASD, DS, FP, MS | 87 (5.7%) | PS | Stromland et al., |
| Valproic acid | Introduced as anticonvulsant and later mood-stabilizer primarily in the treatment of epilepsy and bipolar disorder; but also to treat migraine, headaches and schizophrenia. | Deduced to days 20–24 of gestation | ASD, FVS | 19 | PS | Ardinger et al., |
| 1 | CR | Christianson et al., | ||||
| 40 | CR | Koch et al., | ||||
| 1 | CR | Williams and Hersh, | ||||
| 57 (11%) | PS | Moore et al., | ||||
| 5 | CR | Williams et al., | ||||
| 77 (11.7%) | PS | Rasalam et al., | ||||
Abbreviations: ASD, autism spectrum disorder; CR, case report; CRS, congenital rubella syndrome; DS, Duane syndrome; FAS, fetal alcohol syndrome; FP, face paresis; FVS, fetal valproate syndrome; MS, Möbius syndrome; PS, population study.
1 Sulik et al., 1986.
2 Rodier et al., 1996, 1997; Arndt, 2005.
3 Rodier et al., 1996, 1997; Schneider and Przewlocki, 2005; Markram et al., 2007.
Anatomical and morphological alterations in the VPA rat model of autism.
| Neuron | Measurement | ROI | Effect | Gender | Dose (mg/kg) | ED VPA admin | PND testing | Reference |
|---|---|---|---|---|---|---|---|---|
| Motor neurons | Cell number | Trigeminal Ncl | Reduced | M, F | 350 | 11.5 | 11 | Rodier et al., |
| Motor neurons | Cell number | Trigeminal Ncl | Reduced | M, F | 350 | 12 | 11 | Rodier et al., |
| Motor neurons | Cell number | Trigeminal Ncl | Reduced | M, F | 350 | 12.5 | 10 | Rodier et al., |
| Motor neurons | Cell number | Trigeminal Ncl | No effect | M, F | 350 | 12.5 | 60 | Rodier et al., |
| Motor neurons | Cell number | Hypoglossal Ncl | Reduced | M, F | 350 | 11.5 | 11 | Rodier et al., |
| Motor neurons | Cell number | Hypoglossal Ncl | Reduced | M, F | 350 | 12 | 11 | Rodier et al., |
| Motor neurons | Cell number | Hypoglossal Ncl | Reduced | M, F | 350 | 12.5 | 10 | Rodier et al., |
| Motor neurons | Cell number | Hypoglossal Ncl | Reduced | M, F | 350 | 12.5 | 60 | Rodier et al., |
| Motor neurons | Cell number | Abducens Ncl | No effect | M, F | 350 | 11.5 | 11 | Rodier et al., |
| Motor neurons | Cell number | Abducens Ncl | Reduced | M, F | 350 | 12 | 11 | Rodier et al., |
| Motor neurons | Cell number | Abducens Ncl | Reduced | M, F | 350 | 12.5 | 10 | Rodier et al., |
| Motor neurons | Cell number | Abducens Ncl | No effect | M, F | 350 | 12.5 | 60 | Rodier et al., |
| Motor neurons | Cell number | Oculomotor Ncl | No effect | M, F | 350 | 11.5 | 11 | Rodier et al., |
| Motor neurons | Cell number | Oculomotor Ncl | No effect | M, F | 350 | 12 | 11 | Rodier et al., |
| Motor neurons | Cell number | Oculomotor Ncl | Reduced | M, F | 350 | 12.5 | 10 | Rodier et al., |
| Motor neurons | Cell number | Oculomotor Ncl | Reduced | M, F | 350 | 12.5 | 60 | Rodier et al., |
| Motor neurons | Cell number | Facial Ncl | No effect | M, F | 350 | 11.5 | 11 | Rodier et al., |
| Motor neurons | Cell number | Facial Ncl | No effect | M, F | 350 | 12 | 11 | Rodier et al., |
| Motor neurons | Cell number | Facial Ncl | No effect | M, F | 350 | 12.5 | 10 | Rodier et al., |
| Motor neurons | Cell number | Facial Ncl | No effect | M, F | 350 | 12.5 | 60 | Rodier et al., |
| Neurons | Cell number | Mesencephalic Ncl of CN V | No effect | M, F | 350 | 11, 12, 12.5 | 10 | Rodier et al., |
| Neurons | Cell number | Locus coeruleus | No effect | M, F | 350 | 11, 12, 12.5 | 10 | Rodier et al., |
| Neurons | Cell number | Dorsal motor Ncl of CN X | No effect | M, F | 350 | 11, 12, 12.5 | 10 | Rodier et al., |
| Purkinje cells | Cell number | Cb-vermis | Reduced | M, F | 600 | 12.5 | 40 | Ingram et al., |
| Purkinje cells | Cell number | Cb-hemisphere | No effect | M, F | 600 | 12.5 | 40 | Ingram et al., |
| Pyramidal neurons | Cell number | S1 | No effect | M | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Pyramidal neurons | Gross somatic, axonal and dendritic structure | S1 | No effect | M | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Pyramidal neurons | Spine and bouton density | S1 | No effect | M | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Pyramidal neurons | Synaptic contact number | S1 | Reduced by 40% | M | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Pyramidal neurons | Apoptosis | S1 | No effect | M | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Volume | Overall | Reduced | M, F | 600 | 12.5 | 40 | Ingram et al., | |
| Volume | Cb-vermis | Reduced | M, F | 600 | 12.5 | 40 | Ingram et al., | |
| Volume | Cb-hemisphere | Reduced | M, F | 600 | 12.5 | 40 | Ingram et al., | |
| Cell density | Cb-vermis | No effect | M, F | 600 | 12.5 | 40 | Ingram et al., | |
| Cell density | Cb-hemisphere | No effect | M, F | 600 | 12.5 | 40 | Ingram et al., | |
| Weight | Overall | Reduced | M, F | 350 | 12.5 | 10 | Rodier et al., | |
| Weight | Overall | Reduced | M, F | 350 | 12.5 | 60 | Rodier et al., | |
Results describe the VPA-treated offspring group relative to controls. All studies were performed on rats. Abbreviations: ED, embryonic day; F, female; M, male; N, number; Ncl, nucleus; PND, postnatal day; ROI, region of interest; VPA, valproic acid. ROI: Cb, cerebellum; CN, cranial nerve; S1, primary sensory cortex.
Neurochemical and genetic alterations in the VPA rat model of autism.
| Neurochemical system | Measurement | ROI | Effect | Dose (mg/kg) | ED VPA admin | PND testing | Reference |
|---|---|---|---|---|---|---|---|
| Dopamin | expression | Frontal cortex | Enhanced | 800 | 9 | 35 | Narita et al., |
| Serotonin | 5-HT expression | Frontal cortex | Enhanced | 800 | 9 | 56–105 | Tsujino et al., |
| Serotonin | 5-HT expression | Frontal cortex | No effect | 800 | 9 | 50 | Narita et al., |
| Serotonin | 5-HT expression | Hippocampus | Enhanced | 800 | 9 | 50 | Narita et al., |
| Serotonin | 5-HT expression | Cerebellum | Enhanced | 800 | 9 | 50 | Narita et al., |
| Serotonin | 5-HT expression | Medulla | No effect | 800 | 9 | 50 | Narita et al., |
| Serotonin | 5-HT expression | Plasma | Enhanced | 800 | 9 | 50 | Narita et al., |
| Serotonin | 5-HT positive cell count | dR, overall | No effect | 800 | 9 | 50 | Miyazaki et al., |
| Serotonin | 5-HT positive cell count | dR, overall | Enhanced, but not significant | 800 | 9 | 91, 119 | Tsujino et al., |
| Serotonin | 5-HT positive cell count | dR, rostral to caudal | Enhanced caudally | 800 | 9 | 50 | Miyazaki et al., |
| Serotonin | 5-HT positive cell count | dR, rostral to caudal | Enhanced caudally | 800 | 9 | 91, 119 | Tsujino et al., |
| AMPAR | GluR1 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AMPAR | GluR2 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AMPAR | GluR3 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AMPAR | pGluR1-S831 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AMPAR | pGluR1-S845 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| NMDAR | NR1 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| NMDAR | NR2A expression | S1 | Enhanced | 500 | 12.5 | 12–16 | Rinaldi et al., |
| NMDAR | NR2B expression | S1 | Enhanced | 500 | 12.5 | 12–16 | Rinaldi et al., |
| NMDAR | pNR1-S896 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| NMDAR | pNR1-S897 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| NMDAR | pNR2B-S1303 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| mGluR | mGluR1 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| mGluR | mGluR5 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| mGluR | mGluR4 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| mGluR | mGluR6/7 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Kainate receptor | GluR6/7 expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| CREB | expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| pCREB-S133 | expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| CamKII | expression | S1 | Enhanced | 500 | 12.5 | 12–16 | Rinaldi et al., |
| pCamKII-T286/287 | expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| ERK | expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| perk-Thr202/Tyr204 | expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Enkephalin | PENK mRNA expression | CeA | No effect | 600 | 12.5 | 60–90 | Schneider et al., 2007 |
| Enkephalin | PENK mRNA expression | Dorsal striatum | Reduced | 600 | 12.5 | 60–90 | Schneider et al., 2007 |
| Enkephalin | PENK mRNA expression | Ncl accumbens | Reduced | 600 | 12.5 | 60–90 | Schneider et al., 2007 |
| β-Actin | expression | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Shh | mRNA expression | Whole embryo | Reduced | 800 | 9 | GD 11 | Miyazaki et al., |
| Hoxa1 | mRNA expression | Whole embryo | Enhanced on GD 10, 12, 13, 14 | 600 | 10, 12–15 | 1 hours post-treatment | Stodgell et al., |
| Hoxa1 | mRNA expression | Brain stem | Enhanced | 600 | 12.5 | 2 hours post-treatment | Stodgell et al., |
Results describe the VPA-treated offspring group relative to controls. All studies were performed on male rats. Abbreviations: AMPAR, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CamKII, calcium-calmodulin-dependent protein kinase type 2; CREB, cAMP response element binding protein; ERK, extracellular signal-regulated kinase; ED, embryonic day; F, female; M, male; mGluR, metabotropic glutamate receptor; mRNA, messenger ribonucleic acid; N, number; NMDAR, N-Methylaspartate receptor; PENK, proenkephalin; PND, postnatal day; ROI, region of interest; shh, sonic hedgehog; VPA, valproic acid. ROI: CeA, central nucleus amygdala; dR, dorsal raphe nucleus; S1, primary sensory cortex.
Behavioural alterations in the VPA rat model of autism.
| Function | Task | Effect | Species | Gender | Dose (mg/kg) | GD VPA admin | PND testing | Reference |
|---|---|---|---|---|---|---|---|---|
| Vestibular function, motor development, | Negative geotaxis | No effect | Rat | M | 600 | 12.5 | 7–10 | Schneider and Przewlocki, |
| Vestibular function, motor development, | Negative geotaxis | No effect | Mouse | M, F | 600 | 13 | 13–19 | Wagner et al., |
| Motor development | Surface righting | Impaired | Mouse | M, F | 600 | 13 | 5–9 | Wagner et al., |
| Motor development | Mid-air righting | Impaired | Mouse | M, F | 600 | 13 | 13–19 | Wagner et al., |
| Motor development | Hanging wire grip strength | Enhanced | Mouse | M, F | 200 | 13 | 13–19 | Wagner et al., |
| Motor development | Balance beam | No effect | Mouse | M, F | 600 | 13 | 20–26 | Wagner et al., |
| Motor development | Swim performance | Impaired | Rat | M | 600 | 12.5 | 8, 12 | Schneider and Przewlocki, |
| Motor development | Swim performance | No effect | Rat | M | 600 | 12.5 | 10, 16 | Schneider and Przewlocki, |
| Locomotion | Open field | Enhanced | Rat | 800 | 9 | 18 | Tsujino et al., | |
| Locomotion | Opto-Varimex cage | Enhanced | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Locomotion | Opto-Varimex cage | Enhanced | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Locomotion | Plexi-glass box | Enhanced | Mouse | M, F | 600 | 13 | 20–26 | Wagner et al., |
| Locomotion | EPM | No effect | Rat | M, F | 500 | 12.5 | 110–120 | Markram et al., |
| Vestibular function, motor development | Negative geotaxis | Impaired | Mouse | M, F | 200 | 12–17 | 13–19 | Wagner et al., |
| Motor development | Surface righting | No effect | Mouse | M, F | 200 | 12–17 | 5–9 | Wagner et al., |
| Motor development | Mid-air righting | No effect | Mouse | M, F | 200 | 12–17 | 13–19 | Wagner et al., |
| Motor development | Hanging wire grip strength | No effect | Mouse | M, F | 200 | 12–17 | 13–19 | Wagner et al., |
| Motor development | Balance beam | No effect | Mouse | M, F | 200 | 12–17 | 20–26 | Wagner et al., |
| Motor development | Swim performance | No effect | Rat | M, F | 150 | 7–18 | 50 | Vorhees, |
| Motor development | Swim performance | Impaired | Rat | M, F | 200 | 7–18 | 50 | Vorhees, |
| Locomotion | Activity meter | No effect | Rat | M, F | 150 | 7–18 | 7,9, 11 | Vorhees, |
| Locomotion | Activity meter | No effect | Rat | M, F | 200 | 7–18 | 7,9, 11 | Vorhees, |
| Locomotion | Open field | No effect | Rat | M, F | 150 | 7–18 | 40–42 | Vorhees, |
| Locomotion | Open field | No effect | Rat | M, F | 200 | 7–18 | 40–42 | Vorhees, |
| Locomotion | Plexi-glass box | No effect | M | M, F | 200 | 12–17 | 20–26 | Wagner et al., |
| Exploration | Hole board | Reduced | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Exploration | Hole board | Reduced | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Activity, Eploration | Figure 8 | No effect | Rat | M, F | 150 | 7–18 | 40–42 | Vorhees, |
| Activity, Eploration | Figure 8 | No effect | Rat | M, F | 200 | 7–18 | 40–42 | Vorhees, |
| Eploration | Hole board | Enhanced | Rat | M, F | 150 | 7–18 | 45 | Vorhees, |
| Eploration | Hole board | Reduced | Rat | M, F | 200 | 7–18 | 45 | Vorhees, |
| Locomotion under 12 hours light/dark cycle | Plastic cages | Enhanced in light phase | Rat | 800 | 9 | 28–43 | Tsujino et al., | |
| Feeding under 12 hours light/dark cycle | Plastic cages | Impaired cycle variation | Rat | 800 | 9 | 28–43 | Tsujino et al., | |
| Olfactory | Olfactory discrimination, nest seeking | Impaired | Rat | M | 600 | 12.5 | 9 | Schneider et al., |
| Olfactory | Olfactory discrimination, nest seeking | No effect | Rat | M | 600 | 12.5 | 10, 11 | Schneider and Przewlocki, |
| Tactile | Von Frey test | Enhanced | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Tactile | Von Frey test | No effect | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Auditory | Auditory startle | No effect | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Auditory | Auditory startle | No effect | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Auditory | Auditory startle | No effect | Rat | M, F | 500 | 12.5 | 80–90 | Markram et al., |
| Sensori-motor gating | PPI | Reduced | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Sensori-motor gating | PPI | Reduced | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Sensori-motor gating | PPI | Reduced | Rat | M, F | 500 | 12.5 | 80–90 | Markram et al., |
| Auditory | Auditory startle | No effect | Rat | M, F | 150 | 7–18 | 85 | Vorhees, |
| Auditory | Auditory startle | Reduced | Rat | M, F | 200 | 7–18 | 85 | Vorhees, |
| Tactile | Air-puff startle | No effect | Rat | M, F | 150 | 7–18 | 85 | Vorhees, |
| Tactile | Air-puff startle | Reduced | Rat | M, F | 200 | 7–18 | 85 | Vorhees, |
| Tactile | Tail flick | Reduced | Rat | M | 600 | 12.5 | <30 | Schneider et al., |
| Tactile | Tail flick | Reduced | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Tactile | Tail flick | Reduced | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Tactile | Tail flick | Reduced | Rat | M | 600 | 12.5 | >90 | Schneider et al., |
| Thermal | Hot plate | No effect | Rat | M | 600 | 12.5 | <30 | Schneider et al., |
| Thermal | Hot plate | Reduced | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Thermal | Hot plate | Reduced | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Thermal | Hot plate | Reduced | Rat | M | 600 | 12.5 | >90 | Schneider et al., |
| Thermal | Hot plate | Reduced | Rat | M, F | 500 | 12.5 | 80–90 | Markram et al., |
| Anxiety | EPM | Enhanced | Rat | M | 600 | 12.5 | 30–50 | Schneider et al., |
| Anxiety | EPM | Enhanced | Rat | M | 600 | 12.5 | 60–90 | Schneider et al., 2007 |
| Anxiety | EPM | Enhanced | Rat | M | 600 | 12.5 | 90–120 | Schneider et al., |
| Anxiety | EPM | Enhanced | Rat | M, F | 500 | 12.5 | 110–120 | Markram et al., |
| Anxiety | Open field | No effect | Rat | M, F | 150 | 7–18 | 40–42 | Vorhees, |
| Anxiety | Open field | Enhanced | Rat | M, F | 200 | 7–18 | 40–42 | Vorhees, |
| Social behaviour | Free interaction | Impaired | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Social behaviour | Free interaction | Impaired | Rat | M, F | 500 | 12.5 | 90–100 | Markram et al., |
| Social behaviour | Free interaction | Impaired | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Repetitive behaviour | Opto-Varimex cage | Enhanced | Rat | M | 600 | 12.5 | 30–50 | Schneider and Przewlocki, |
| Repetitive behaviour | Opto-Varimex cage | Enhanced | Rat | M | 600 | 12.5 | 90–120 | Schneider and Przewlocki, |
| Spontan. alterations | Y-maze | Reduced | Rat | M, F | 500 | 12.5 | 80–90 | Markram et al., |
| Spontan. alterations | T-maze | No effect | Rat | M, F | 150 | 7–18 | 70 | Vorhees, |
| Spontan. alterations | T-maze | Reduced | Rat | M, F | 200 | 7–18 | 70 | Vorhees, |
| Spatial learning | Morris water maze | Impaired | Mouse | M, F | 600 | 13 | 20–26 | Wagner et al., |
| Spatial learning | Object recognition | No effect | Rat | M | 600 | 12.5 | 60–90 | Schneider et al., 2007 |
| Spatial learning | Morris water maze | No effect | Rat | M, F | 500 | 12.5 | 90–110 | Markram et al., |
| Eye blink conditioning | Discriminative eye-blink conditioning | Enhanced | Rat | M, F | 600 | 12 | 26–31 | Stanton et al., 2006 |
| Fear conditioning | Auditory fear conditioning training | No effect | Rat | M, F | 500 | 12.5 | 120–122 | Markram et al., |
| Fear conditioning | Auditory fear generalization | Enhanced | Rat | M, F | 500 | 12.5 | 124 | Markram et al., |
| Fear conditioning | Auditory fear memory | Enhanced | Rat | M, F | 500 | 12.5 | 124–174 | Markram et al., |
| Fear conditioning | Contextual fear memory | Enhanced | Rat | M, F | 500 | 12.5 | 123–173 | Markram et al., |
| Conditioned place aversion | Conditioned place aversion to naloxone | Impaired | Rat | M | 600 | 12.5 | 60–90 | Schneider et al., 2007 |
| Fear extinction | Contextual fear extinction | Impaired | Rat | M, F | 500 | 12.5 | 174–180 | Markram et al., |
| Fear extinction | Tone fear extinction in same context | Impaired | Rat | M, F | 500 | 12.5 | 174–180 | Markram et al., |
| Fear extinction | Tone fear extinction in different context | No effect | Rat | M, F | 500 | 12.5 | 174–180 | Markram et al., |
| Reversal learning | Discriminative eye-blink reversal | Impaired | Rat | M, F | 600 | 12 | 26–31 | Stanton et al., 2006 |
| Spatial learning | Cincinnati water maze | No effect | Rat | M, F | 150 | 7–18 | 51–54; 57–58 | Vorhees, |
| Spatial learning | Cincinnati water maze | No effect | Rat | M, F | 200 | 7–18 | 51–54; 57–58 | Vorhees, |
| Spatial learning | Morris water maze | No effect | Mouse | M, F | 200 | 12–17 | 20–26 | Wagner et al., |
| Spatial reversal learning | Cincinnati water maze | No effect | Rat | M, F | 150 | 7–18 | 59–61; 64–66 | Vorhees, |
| Spatial reversal learning | Cincinnati water maze | M No effect F Impaired | Rat | M, F | 200 | 7–18 | 59–61; 64–66 | Vorhees, |
Results describe the VPA-treated offspring group relative to controls. Abbreviations: ED, embryonic day; EPM, elevated plus maze; F, female; M, male; N, number; PND, postnatal day; PPI, pre-pulse inhibition; VPA, valproic acid.
Microcircuit alterations in the VPA rat model of autism.
| Measurement | Region | Effect | Dose (mg/kg) | ED VPA admin | PND testing | Reference |
|---|---|---|---|---|---|---|
| NMDAR current influx | S1 | Enhanced | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AMPAR current influx | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AMPA/NMDA current influx ratio | S1 | Decreased | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AP evoked calcium transients | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Direct and disynaptic connectivity between layer 5 pyramidal neurons less than 50 μm apart | S1 | Enhanced by more than 50% | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Direct and disynaptic connectivity between layer 5 pyramidal neurons 100–200 μm apart | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Strength of direct connections between layer 5 pyramidal neurons | S1 | Decreased | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Electrical excitability of layer 2/3 and 5 neurons | S1 | Decreased | 500 | 12.5 | 12–16 | Rinaldi et al., |
| AP amplitude, threshold, input resistance | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Network reactivity to excitatory inputs in layer 2/3 and layer 5 (voltage clamp at GABAA reversal potential ∼ −57 mV) | S1 | Enhanced | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Network reactivity to inhibitory inputs in layer 2/3 and layer 5 (voltage clamp at AMPA reversal potential ∼+10 mV) | S1 | Enhanced | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Network excitatory/inhibitory balance | S1 | No effect | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Network reactivity to excitatory inputs (voltage clamp at GABAA reversal potential ∼−57 mV) | LA | Enhanced | 500 | 12.5 | 12–16 | Markram et al., |
| Network reactivity to inhibitory inputs (voltage clamp at AMPA reversal potential ∼+10 mV) | LA | Decreased | 500 | 12.5 | 12–16 | Markram et al., |
| Reverberant activity | LA | Enhanced | 500 | 12.5 | 12–16 | Markram et al., |
| Postsynaptic LTP | S1 | Enhanced | 500 | 12.5 | 12–16 | Rinaldi et al., |
| Postsynaptic LTP | LA | Enhanced | 500 | 12.5 | 12–16 | Markram et al., |
Results describe the VPA-treated offspring group relative to controls. All studies were performed on male rats. Abbreviations: AP, action potential; ED, embryonic day; LA, lateral nucleus of the amygdala; LTP, long-term potential; M, male; S1, primary somatosensory cortex; VPA, valproic acid.